

OneSource Announces FY26 Results with Strong Q4 Performance; Reaffirms FY28 Guidance

Revenue up 47% QoQ and EBITDA expanding more than 5x, supported by broad business momentum and India semaglutide launches

Performance Highlights

- Revenues at ₹4,282 million, up 47% QoQ, driven by growth across all service offerings supported by India semaglutide commercial launch
- EBITDA at ₹919 million, 5x+ quarter-on-quarter, reflecting operating leverage on higher CSA revenues during the quarter
- Adjusted PAT stood at ₹390 million with adjusted EPS of ₹3.4

FY28 Guidance Reaffirmation

- ~\$400 million in organic revenue with ~40% EBITDA margin

Bangalore, India, May 13, 2026 – OneSource Specialty Pharma Limited (BSE:544292, NSE: ONESOURCE) today announced its consolidated financial results for the quarter (Q4FY26) and full year ended March 31, 2026.

Financial Highlights (In ₹ million)

Particulars	Q4FY26	Q3FY26	QoQ	FY26	FY25	YoY
Revenues	4,282	2,903	47%	14,216	14,449	(2%)
EBITDA	919	173	5x+	3,042	4,665	(35%)
EBITDA %	21%	6%	1550bps	21%	32%	(1089bps)
Adjusted PAT ¹	390	(472)	Loss to profit	739	2,314	(68%)
Adjusted EPS ¹	3.4	(4.1)	Loss to profit	6.5	21.0	(69%)

Note: Adjusted PAT and Adjusted EPS excludes exceptional items (Q4FY26: ₹0.3m, Q3FY26: ₹71m, FY26: ₹99m, FY25: ₹1,108m) and scheme related intangible amortisation (Q4FY26: ₹344m, Q3FY26: ₹344m, FY26: ₹1,378, FY25: ₹1,413m).

Mr. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma Limited speaking on the performance said, “We saw a strong recovery in Q4 driven by broad-based business performance. The quarter was marked by successful semaglutide launches in India across multiple customer brands, alongside new launches in the US injectables and soft-gelatin businesses. With the recent back-to-back semaglutide approvals in Canada and continued expansion of our biologics pipeline, we are well positioned to sustain growth momentum into FY27.”

Detailed investor communication on the performance of the Company is attached.

About OneSource Specialty Pharma Limited

OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,600 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. For more information, please visit www.onesourcecdmo.com.

For further information, please contact:

<p>Institutional Investors Anurag Bhagania CFO</p> <p>Tejaswani Fotedar +91 9004331391 Email: investor-relations@onesourcecdmo.com</p>	<p>Corporate Communication Pallavi Panchmatia: +91 8951939181 Email: pallavi.panchmatia@onesourcecdmo.com</p> <p>Abhilash Mukherjee: +91 89044 28907 Email: abhilash.mukherjee@onesourcecdmo.com</p> <p>Harsh Sheth: +91 9870631557 Email: harsh.sheth@msslgroup.com</p>
---	---